ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib
Keyword(s):
2018 ◽
Vol 10
(446)
◽
pp. eaau0472
◽
2015 ◽
pp. 485-491
◽
Keyword(s):
2020 ◽
Vol 573
◽
pp. 118842
◽
Keyword(s):
2013 ◽
Vol 33
(5)
◽
pp. 375-381
◽
Keyword(s):
2011 ◽
Vol 40
(3)
◽
pp. 515-521
◽
Keyword(s):
2006 ◽
Vol 34
(4)
◽
pp. 690-695
◽
1989 ◽
Vol 56
(2)
◽
pp. 97-102
◽
Keyword(s):